Biotechnology, Innovation and Health oecd.org - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from oecd.org Daily Mail and Mail on Sunday newspapers.
LLNL physicist Matthias Frank measures the movement of DNATrax surrogate particles in a test chamber.
Lawrence Livermore National Laboratory (LLNL) scientists are leveraging their extensive experience studying the movement of airborne hazards to better understand the movement of virus-like particles through the air and to identify effective countermeasures.
DNATrax released in a conference room.
While the burden of airborne diseases is known to be large, its true scope is underappreciated. LLNL researchers recently published a review in the journal Applied and Environmental Microbiology that highlights well-established cases of airborne viruses, bacteria and fungal pathogens causing disease in plants, animals and humans over distance scales ranging from a few meters to continental.
A compact wastewater treatment system developed by the Department of Science and Technology-Industrial Technology Development Institute (ITDI) is now available for adoption as part of DoST efforts to help reduce environmental degradation in Boracay and Manila Bay.
Lawrence Livermore National Laboratory announced this week a new collaboration with a United Kingdom company to develop a broad-spectrum or "universal" coronavirus vaccine.
Date Time
LLNL and United Kingdom company to collaborate on development of universal coronavirus vaccine
LLNL researchers Nick Fischer and Amy Rasley are characterizing nanolipoprotein particle vaccine formulations using a dynamic light-scattering instrument. Detailed characterization of the nanoparticles provides an important quality control metric for vaccine development. A United Kingdom company, ConserV Bioscience Limited, and LLNL have agreed to work on developing a universal coronavirus vaccine. Photo by Julie Russell/LLNL (taken pre-pandemic).
ConserV Bioscience Limited (CBL) and Lawrence Livermore National Laboratory (LLNL) have agreed to collaborate on the development of a broad-spectrum or “universal” coronavirus vaccine.
This collaboration brings together CBL’s expertise in identifying antigens and LLNL’s nanolipoprotein delivery system. The vaccine has been designed to provide broad-spectrum protection against coronavirus pathogens of human and animal origin,